Robert Weingarten - Lixte Biotechnology VP CFO
| LIXT Stock | USD 2.23 0.06 2.76% |
Insider
Robert Weingarten is VP CFO of Lixte Biotechnology Holdings
| Age | 72 |
| Address | 680 East Colorado Boulevard, Pasadena, CA, United States, 91101 |
| Phone | 631 830 7092 |
| Web | https://lixte.com |
Robert Weingarten Latest Insider Activity
Tracking and analyzing the buying and selling activities of Robert Weingarten against Lixte Biotechnology stock is an integral part of due diligence when investing in Lixte Biotechnology. Robert Weingarten insider activity provides valuable insight into whether Lixte Biotechnology is net buyers or sellers over its current business cycle. Note, Lixte Biotechnology insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lixte Biotechnology'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Robert Weingarten over six months ago Acquisition by Robert Weingarten of 200000 shares of Lixte Biotechnology subject to Rule 16b-3 |
Lixte Biotechnology Management Efficiency
The company has return on total asset (ROA) of (0.8733) % which means that it has lost $0.8733 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.6333) %, meaning that it created substantial loss on money invested by shareholders. Lixte Biotechnology's management efficiency ratios could be used to measure how well Lixte Biotechnology manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.24 in 2024. Return On Capital Employed is likely to drop to -1.34 in 2024. Change To Liabilities is likely to gain to about 106.3 K in 2024, whereas Total Current Liabilities is likely to drop slightly above 290.7 K in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Winston MBA | Pmv Pharmaceuticals | 48 | |
| Claus Pedersen | Allarity Therapeutics | 52 | |
| James Foster | Virax Biolabs Group | 39 | |
| Michael Myers | Quoin Pharmaceuticals Ltd | 62 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| Gordon JD | Quoin Pharmaceuticals Ltd | 60 | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Jason Davis | Virax Biolabs Group | 52 | |
| Annie Rasmussen | Allarity Therapeutics | 67 | |
| Peter Kushner | Olema Pharmaceuticals | 85 | |
| MBA MD | Scholar Rock Holding | 57 | |
| PharmD BCPS | Neurobo Pharmaceuticals | N/A | |
| MSc MBA | Passage Bio | 55 | |
| David Myles | Olema Pharmaceuticals | 61 | |
| Deepika PharmD | Pmv Pharmaceuticals | 47 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| MD DrSc | Allarity Therapeutics | 81 | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
| Professor MD | Allarity Therapeutics | 67 | |
| Daniel Schneiderman | Pasithea Therapeutics Corp | 46 | |
| Caryn Parlavecchio | Scholar Rock Holding | 52 | |
Management Performance
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 |
Lixte Biotechnology Leadership Team
Elected by the shareholders, the Lixte Biotechnology's board of directors comprises two types of representatives: Lixte Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lixte. The board's role is to monitor Lixte Biotechnology's management team and ensure that shareholders' interests are well served. Lixte Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lixte Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bastiaan MSc, CEO President | ||
| Johannes MD, Chief Officer | ||
| James MD, Chief Officer | ||
| Robert Weingarten, VP CFO | ||
| Eric JD, VP COO | ||
| John MD, President, Founder |
Lixte Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lixte Biotechnology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.63 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 6.88 M | ||||
| Shares Outstanding | 2.25 M | ||||
| Shares Owned By Insiders | 20.40 % | ||||
| Shares Owned By Institutions | 9.64 % | ||||
| Number Of Shares Shorted | 189.13 K | ||||
| Price To Earning | (2.96) X | ||||
| Price To Book | 12.00 X | ||||
| EBITDA | 3.21 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lixte Stock Analysis
When running Lixte Biotechnology's price analysis, check to measure Lixte Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotechnology is operating at the current time. Most of Lixte Biotechnology's value examination focuses on studying past and present price action to predict the probability of Lixte Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lixte Biotechnology's price. Additionally, you may evaluate how the addition of Lixte Biotechnology to your portfolios can decrease your overall portfolio volatility.